The Pharma Data

OCTOBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. President and Chief Executive Officer of Tonix Pharmaceuticals. About Tonix Pharmaceuticals Holding Corp. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

Drug Target Review

MAY 23, 2023

Algae – an overlooked resource for new therapies It is only in recent years that algae research has expanded beyond their potential for producing biodiesel, to also consider them as a bio-resource, not only for novel prebiotics but also for compounds with unique structures and pharmaceutically relevant bioactivities.

Drugs 75

Drugs Small Molecule Production Disease 75

The Pharma Data

MAY 2, 2023

Starting in 2026, this facility will develop manufacturing processes for active pharmaceutical ingredients and produce drugs for use in clinical trial phases. The pharmaceutical industry has a long tradition in Rhineland-Palatinate. Germany and Europe can enhance their resilience by establishing local value chains.

Small Molecule 40

Small Molecule Clinical Trials Pharmaceuticals Pharmaceutical Companies 40

The Pharma Data

JULY 18, 2021

Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. Source link: [link].

Licensing 52

Licensing Licensing Vaccine FDA 52

The Pharma Data

DECEMBER 21, 2020

22, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. government agencies and other institutions. RESEARCH TRIANGLE PARK, N.C., The trial was not designed or sized to demonstrate clinical efficacy and no clinical efficacy benefit with galidesivir treatment compared to placebo treatment was observed in the trial.

Clinical Trials 52

Clinical Trials Virus RNA Trials 52

The Pharma Data

JANUARY 26, 2021

Food and Drug Administration’s Office of Orphan Products Development has granted Orphan Drug Designation to Uttroside-B , a small molecule chemotherapeutic for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. (OTCQB: QBIO), announced today that the U.S. billion by 2027.

Treatment 40

Treatment FDA Small Molecule Drugs 40

The Pharma Data

JANUARY 19, 2021

–( BUSINESS WIRE )– Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, announced today that it has priced an underwritten public offering of 5,400,000 shares of common stock at a public offering price of $14.00 About Syros Pharmaceuticals. 20, 2021 03:41 UTC.

Small Molecule 52

Small Molecule Clinical Trials Pharmaceuticals Virus 52

The Pharma Data

JUNE 17, 2022

government. government’s commitment to free access to COVID-19 vaccines. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52

The Pharma Data

APRIL 15, 2022

Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. Source link: [link].

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

The Pharma Data

MARCH 16, 2022

Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. Source link: [link].

Vaccine 52

Vaccine Small Molecule FDA Disease 52

The Pharma Data

FEBRUARY 24, 2022

Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. Source link: [link].

Vaccine 52

Vaccine FDA Small Molecule Immune Response 52

Precision for Medicine

JUNE 26, 2023

“Our partnerships are with the most innovative organizations, utilizing the most advanced, cutting-edge technologies and providing us with unparalleled experience in manufacturing small molecule, biologics and next-generation medicines,” said John Khoury, Executive Vice President at Project Farma.

Science 40

Science Small Molecule Clinical Research Engineering 40

The Pharma Data

NOVEMBER 5, 2020

X4 Pharmaceuticals – Art Taveras was named CSO of Cambridge, Mass.-based Prior to that, Taveras was vice president of Small Molecule Drug Discovery and CMC Development at Biogen Idec, and Alantos Pharmaceuticals, which was acquired by Amgen in 2007. Before GSK, Rosén was senior vice president, U.S.

Analytical Chemistry 40

Analytical Chemistry Pharmaceuticals Small Molecule Therapies 40

The Pharma Data

FEBRUARY 18, 2022

BioNTech will be responsible for the delivery and installation of the modules, while local organizations, authorities and governments will ensure the needed infrastructure. BioNTech expects to ship BioNTainers to Rwanda, Senegal and potentially South Africa in close coordination with the respective country and the African Union.

Vaccine 40

Vaccine Production Small Molecule Therapies 40

The Pharma Data

DECEMBER 5, 2020

–(BUSINESS WIRE) December 5, 2020 — Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced new clinical data from its Phase 2 trial evaluating SY-1425, its first-in-class selective retinoic acid receptor alpha (RAR?) Source: Syros Pharmaceuticals.

Clinical Trials 52

Clinical Trials Trials Small Molecule Treatment 52

The Pharma Data

SEPTEMBER 12, 2020

Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more information, please visit www.BioNTech.de.

Vaccine 52

Vaccine Trials Clinical Trials Small Molecule 52

The Pharma Data

SEPTEMBER 9, 2020

Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more information, please visit www.BioNTech.de.

Vaccine 52

Vaccine Clinical Trials Trials Government 52

The Pharma Data

JULY 21, 2021

The companies are firmly committed to working towards equitable and affordable access for COVID-19 vaccines for all people around the world, actively working with global governments as well as global health partners with the aim to provide 2 billion doses to low and middle income countries in 2021 and 2022 – 1 billion each year.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

MAY 6, 2021

Under the MoU framework, NOCs and their local governments are expected to coordinate the administration of vaccinations to eligible Games participants. Doses provided under this MoU would be in addition to doses provided under supply agreements with governments worldwide. For more information, please visit www.BioNTech.de.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

NOVEMBER 20, 2020

In some cases, governments may have regulatory pathways similar to an EUA. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.

Vaccine 52

Vaccine FDA Clinical Trials Trials 52

The Pharma Data

MAY 7, 2021

Government,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “We Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.

Licensing 52

Licensing Licensing Vaccine FDA Approval 52

The Pharma Data

DECEMBER 12, 2020

12, 2020– AstraZeneca and Alexion Pharmaceuticals, Inc. AstraZeneca has developed a broad range of technologies, initially focused on small molecules and biologics and with a growing focus in precision medicine, genomics, oligonucleotides and epigenetics. Governance. Source: Alexion Pharmaceuticals, Inc.

Regulations 75

Regulations International Disease Small Molecule 75

The Pharma Data

SEPTEMBER 9, 2020

Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more information, please visit www.BioNTech.de.

Vaccine 52

Vaccine Clinical Trials RNA Trials 52

The Pharma Data

DECEMBER 11, 2020

Government to supply doses in 2020 & 2021. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.

Vaccine 52

Vaccine Clinical Trials Trials Licensing 52

The Pharma Data

AUGUST 20, 2020

Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more information, please visit www.BioNTech.de.

Vaccine 52

Vaccine Clinical Trials Trials Immune Response 52

The Pharma Data

DECEMBER 1, 2020

Pfizer and BioNTech continue to work in collaboration with governments and Ministries of Health around the world that will distribute the vaccine, subject to country authorization or approval, to help ensure it can reach those most in need as quickly as possible. Manufacturing and Delivery Capabilities.

Vaccine 40

Vaccine Clinical Trials Trials Production 40

The Pharma Data

NOVEMBER 9, 2020

Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more information, please visit www.BioNTech.de.

Vaccine 40

Vaccine Clinical Trials Trials FDA 40

The Pharma Data

MARCH 13, 2022

NYSE: PFE) announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Pfizer Inc. The root cause of many immunological diseases is immuno-inflammation, which requires specifically designed agents.

Pharmaceuticals 52

Pharmaceuticals Small Molecule Biosimilars Disease 52

The Pharma Data

DECEMBER 4, 2021

Working closely with AWS experts in machine learning and analytics, we aim to provide our scientists and researchers with the insights they need to help deliver medical breakthroughs that change patients’ lives,” said Andrew McKillop, Vice President of Pharmaceutical Sciences, Worldwide Research, Development, and Medical at Pfizer.

Drug Development 52

Drug Development Small Molecule Synthetic Chemistry Drugs 52

DrugBank

FEBRUARY 26, 2025

In response, researchers and pharmaceutical companies are exploring novel approaches to antibiotic development. Over the past two decades, many pharmaceutical companies have deprioritized antibiotic research due to high development costs and lower profitability compared to treatments for chronic diseases.

Therapies 52

Therapies Pharmaceutical Companies Pharmacokinetics Treatment 52

The Pharma Data

MARCH 29, 2022

Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.

Vaccine 52

Vaccine Small Molecule FDA Therapies 52

LifeSciVC

APRIL 27, 2023

Fourteen years on, this corporate experiment has gone far beyond the initial idea, and has established an R&D engine more effective than most big pharma R&D groups at producing best-in-class small molecules against targets that matter in human disease biology. Chapter 1 – An Unreasonable Idea The year was 2009.

Small Molecule 40

Small Molecule Computational Chemistry Engineering Clinical Development 40

The Pharma Data

MARCH 18, 2022

Today marks a major milestone for EUROAPI, a leading European company dedicated to the development, production and marketing of active pharmaceutical ingredients* (API), as Sanofi’s Board of Directors unanimously proposed, on March 17th, to submit to its shareholders the distribution of circa 58% of the share capital of EUROAPI.

Small Molecule 52

Small Molecule Marketing Pharmaceuticals Regulations 52

The Pharma Data

MARCH 4, 2021

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) and Ovid Therapeutics Inc. About Takeda Pharmaceutical Company Limited. A replay of the call will be available on the Ovid Therapeutics website following the completion of the call and will be archived for 30 days. selective GABA A receptor agonist.

Treatment 52

Treatment Pharmaceutical Companies Clinical Trials Trials 52

Agency IQ

OCTOBER 6, 2023

CDER is the FDA office in charge of reviewing pharmaceuticals and therapeutic biologics. All products are received in one of two forms: A New Drug Application (or NDA, for pharmaceuticals) or a Biologics License Application (BLA, for biologics). government fiscal year runs from October 1 – September 30. As a reminder, the U.S.

FDA 52

FDA Biosimilars Science Drugs 52

The Pharma Data

MARCH 29, 2022

Etrasimod was developed by Arena Pharmaceuticals, which was recently acquired by Pfizer. Our differentiated R&D approach resulted in one of the broadest pipelines in the industry, where we purposefully match molecules to diseases where we believe they can make the biggest difference. About Etrasimod.

Trials 52

Trials Small Molecule Disease Biosimilars 52

The Pharma Data

FEBRUARY 25, 2022

Biohaven Pharmaceutical Holding Company Ltd. CGRP Receptor Antagonism Small molecule CGRP receptor antagonists represent a novel class of drugs for the treatment of migraine. NYSE: BHVN) and Pfizer Inc. For more than 170 years, we have worked to make a difference for all who rely on us.

Treatment 52

Treatment Small Molecule FDA Approval Therapies 52